In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee

Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.